Title : Exploiting the metabolic energy demands of drug efflux pumps provides a strategy to overcome multidrug resistance in cancer.

Pub. Date : 2021 Aug

PMID : 33965440






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: P-glycoprotein (P-gp) is a prevalent resistance mediator and it requires considerable cellular energy to ensure ATP dependent efflux of anticancer drugs. Adenosine Triphosphate ATP binding cassette subfamily B member 1 Homo sapiens
2 BACKGROUND: P-glycoprotein (P-gp) is a prevalent resistance mediator and it requires considerable cellular energy to ensure ATP dependent efflux of anticancer drugs. Adenosine Triphosphate ATP binding cassette subfamily B member 1 Homo sapiens
3 The glycolytic pathway generates the majority of catabolic energy in cancer cells; however, the high rates of P-gp activity places added strain on its inherently limited capacity to generate ATP. Adenosine Triphosphate ATP binding cassette subfamily B member 1 Homo sapiens
4 This is particularly relevant for compounds such as verapamil that are believed to trap P-gp in a futile transport process that requires continuing ATP consumption. Adenosine Triphosphate ATP binding cassette subfamily B member 1 Homo sapiens
5 Even in the absence of verapamil, P-gp expressing cells display near maximal rates of glycolysis and oxidative phosphorylation, which prevents an adequate response to the demand for ATP to sustain transport activity. Adenosine Triphosphate ATP binding cassette subfamily B member 1 Homo sapiens
6 CONCLUSIONS: Our results demonstrate that the strained metabolic profiles of P-gp expressing resistant cancer cells can be overwhelmed by additional ATP demands. Adenosine Triphosphate ATP binding cassette subfamily B member 1 Homo sapiens